Hypertension Research最新文献

英文中文

Correction: Personalised hypertension management with accurate blood pressure measurement: much achieved, much more to do.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-26 DOI: 10.1038/s41440-025-02198-9

James E Sharman

引用次数: 0

Early onset of hypertension and increased relative risks of chronic kidney disease and mortality: two population-based cohort studies in United Kingdom and Hong Kong.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-26 DOI: 10.1038/s41440-025-02188-x

Kiki Sn Liu, Boyuan Wang, Ivy L Mak, Edmond Ph Choi, Cindy Lk Lam, Eric Yf Wan

This study aimed to evaluate the association between hypertension (HT) onset age and later risks of chronic kidney diseases (CKD) and mortality. Adult patients without CKD from 2008 to 2013 were identified using electronic medical records from United Kingdom (UK) and Hong Kong (HK). Patients newly diagnosed with HT and those without were included in the HT and control groups, respectively. All subjects were stratified into six age groups (18-39, 40-49, 50-59, 60-69, 70-79, ≥80). Multivariable Cox proportional hazard regression, adjusted with baseline characteristics and fine stratification weights, was conducted to investigate the association between HT onset and risks of CKD, renal decline, end-stage renal disease (ESRD), and all-cause mortality. Subjects were followed up from baseline until an outcome event, death, or administrative end of the cohort, whichever occurred first. A total of 4,413,551 and 3,132,951 subjects were included in the UK and HK cohorts, respectively. HT was significantly associated with increased risks of outcome, but the hazard ratios (HRs) decreased with increasing onset age. In the UK cohort, the HRs (95% confidence intervals) for subjects aged 18-39 and ≥80 were 3.69 (3.53, 3.86) and 2.01 (1.96, 2.06) for CKD, 3.83 (3.60, 4.07) and 3.17 (2.97, 3.38) for renal decline, 17.26 (14.34, 20.77) and 2.55 (2.12, 3.07) for ESRD, 2.88 (2.66, 3.11) and 1.09 (1.07, 1.12) for mortality. The HK cohort exhibited a similar pattern. Our study concluded that early onset of HT significantly affects renal health later in life, while the contribution decreases with the onset age of HT.

{"title":"Early onset of hypertension and increased relative risks of chronic kidney disease and mortality: two population-based cohort studies in United Kingdom and Hong Kong.","authors":"Kiki Sn Liu, Boyuan Wang, Ivy L Mak, Edmond Ph Choi, Cindy Lk Lam, Eric Yf Wan","doi":"10.1038/s41440-025-02188-x","DOIUrl":"https://doi.org/10.1038/s41440-025-02188-x","url":null,"abstract":"This study aimed to evaluate the association between hypertension (HT) onset age and later risks of chronic kidney diseases (CKD) and mortality. Adult patients without CKD from 2008 to 2013 were identified using electronic medical records from United Kingdom (UK) and Hong Kong (HK). Patients newly diagnosed with HT and those without were included in the HT and control groups, respectively. All subjects were stratified into six age groups (18-39, 40-49, 50-59, 60-69, 70-79, ≥80). Multivariable Cox proportional hazard regression, adjusted with baseline characteristics and fine stratification weights, was conducted to investigate the association between HT onset and risks of CKD, renal decline, end-stage renal disease (ESRD), and all-cause mortality. Subjects were followed up from baseline until an outcome event, death, or administrative end of the cohort, whichever occurred first. A total of 4,413,551 and 3,132,951 subjects were included in the UK and HK cohorts, respectively. HT was significantly associated with increased risks of outcome, but the hazard ratios (HRs) decreased with increasing onset age. In the UK cohort, the HRs (95% confidence intervals) for subjects aged 18-39 and ≥80 were 3.69 (3.53, 3.86) and 2.01 (1.96, 2.06) for CKD, 3.83 (3.60, 4.07) and 3.17 (2.97, 3.38) for renal decline, 17.26 (14.34, 20.77) and 2.55 (2.12, 3.07) for ESRD, 2.88 (2.66, 3.11) and 1.09 (1.07, 1.12) for mortality. The HK cohort exhibited a similar pattern. Our study concluded that early onset of HT significantly affects renal health later in life, while the contribution decreases with the onset age of HT.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood pressure at hospital admission: a window into the prognoses of patients with atrial fibrillation.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-26 DOI: 10.1038/s41440-025-02196-x

Takahiro Okumura, Satoshi Yanagisawa, Toyoaki Murohara

引用次数: 0

Microstructural damage and lower myelin content in the Brainstem associated with hypertension.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-26 DOI: 10.1038/s41440-025-02184-1

Joji Ishikawa

引用次数: 0

Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular carcinoma?

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-26 DOI: 10.1038/s41440-025-02197-w

Satoshi Kidoguchi

Lenvatinib, a multi-tyrosine kinase inhibitor approved for the treatment of multiple cancer types, can induce hypertension, which can be a prognostic indicator in patients with hepatocellular carcinoma. Further research into the mechanism of anticancer drug-induced blood pressure elevation is necessary and patients should be managed by a multi-disciplinary "Onco-Hypertension" team.

引用次数: 0

Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-25 DOI: 10.1038/s41440-025-02175-2

Atsuhisa Sato, Mitsuhiro Nishimoto

Finerenone is a new mineralocorticoid receptor antagonist that does not have a steroid skeleton, and in two large-scale clinical studies targeting patients with chronic kidney disease (CKD) complicated with type 2 diabetes (FIDELIO-DKD and FIGARO-DKD), it significantly reduced the composite endpoints due to the progression of renal disease, and the composite endpoints of cardiovascular disease. Recently, we published two databases summarizing how finerenone is used in clinical practice in Japan (FINEROD). In this paper, we examines how best to use finerenone to get the most out of its effects. The most important side effect of finerenone is hyperkalemia, and the risk of hyperkalemia increases as renal function declines. By starting treatment early when eGFR is maintained, it is expected that side effects will be reduced. Furthermore, the FIDELITY analysis (a pooled analysis of FIDELIO-DKD and FIGARO-DKD) has shown that the clinical effect is stronger when finerenone treatment is started at an early stage of CKD. The simultaneous use of RAS inhibitors (ACE inhibitor or ARB), finerenone, and SGLT2 inhibitors appears to be a promising treatment. Further, it is important to continue the medications of RAS inhibitors and MR antagonists as long as possible. To prevent hyperkalemia, the most reliable and safest method is to use a new oral potassium adsorbent. It is important to think of a new oral potassium adsorbent not as something that will lower serum potassium levels, but as something that will allow you to avoid discontinuing or increase the dose of RAS inhibitors or MR antagonists. Differences between steroidal and non-steroidal mineralocorticoid receptor (MR) antagonists. Mineralocorticoid receptors (MR) are present in epithelial tissues such as renal tubules and intestinal epithelium, as well as in non-epithelial tissues such as the brain, heart, and blood vessel walls. Although the MR itself is exactly the same in both tissues, its physiological actions are completely different. In epithelial tissues, cortisol is inactivated by the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11 β-HSD2), and aldosterone selectively binds to the MR. On the other hand, in non-epithelial tissues, 11 β-HSD2 is almost nonexistent or is only weakly active, so that cortisol, which outnumbers it, binds to almost all the MR, and aldosterone binds to the very few remaining MR. Spironolactone, a representative MR antagonist with a steroid skeleton, has a high affinity for renal tubules, and concentrates there, where it is highly effective. Therefore, it is classified as a potassium-sparing diuretic. However, if it does not have a steroid skeleton, its affinity for epithelial and non-epithelial tissues is equal. In other words, its effect on epithelial tissues is relatively weak, and its effect on non-epithelial tissues is relatively strong. Finerenone does not cross the blood-brain barrier (BBB), and does not reach the central nervous system. The central MR, esp

{"title":"Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD.","authors":"Atsuhisa Sato, Mitsuhiro Nishimoto","doi":"10.1038/s41440-025-02175-2","DOIUrl":"10.1038/s41440-025-02175-2","url":null,"abstract":"Finerenone is a new mineralocorticoid receptor antagonist that does not have a steroid skeleton, and in two large-scale clinical studies targeting patients with chronic kidney disease (CKD) complicated with type 2 diabetes (FIDELIO-DKD and FIGARO-DKD), it significantly reduced the composite endpoints due to the progression of renal disease, and the composite endpoints of cardiovascular disease. Recently, we published two databases summarizing how finerenone is used in clinical practice in Japan (FINEROD). In this paper, we examines how best to use finerenone to get the most out of its effects. The most important side effect of finerenone is hyperkalemia, and the risk of hyperkalemia increases as renal function declines. By starting treatment early when eGFR is maintained, it is expected that side effects will be reduced. Furthermore, the FIDELITY analysis (a pooled analysis of FIDELIO-DKD and FIGARO-DKD) has shown that the clinical effect is stronger when finerenone treatment is started at an early stage of CKD. The simultaneous use of RAS inhibitors (ACE inhibitor or ARB), finerenone, and SGLT2 inhibitors appears to be a promising treatment. Further, it is important to continue the medications of RAS inhibitors and MR antagonists as long as possible. To prevent hyperkalemia, the most reliable and safest method is to use a new oral potassium adsorbent. It is important to think of a new oral potassium adsorbent not as something that will lower serum potassium levels, but as something that will allow you to avoid discontinuing or increase the dose of RAS inhibitors or MR antagonists. Differences between steroidal and non-steroidal mineralocorticoid receptor (MR) antagonists. Mineralocorticoid receptors (MR) are present in epithelial tissues such as renal tubules and intestinal epithelium, as well as in non-epithelial tissues such as the brain, heart, and blood vessel walls. Although the MR itself is exactly the same in both tissues, its physiological actions are completely different. In epithelial tissues, cortisol is inactivated by the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11 β-HSD2), and aldosterone selectively binds to the MR. On the other hand, in non-epithelial tissues, 11 β-HSD2 is almost nonexistent or is only weakly active, so that cortisol, which outnumbers it, binds to almost all the MR, and aldosterone binds to the very few remaining MR. Spironolactone, a representative MR antagonist with a steroid skeleton, has a high affinity for renal tubules, and concentrates there, where it is highly effective. Therefore, it is classified as a potassium-sparing diuretic. However, if it does not have a steroid skeleton, its affinity for epithelial and non-epithelial tissues is equal. In other words, its effect on epithelial tissues is relatively weak, and its effect on non-epithelial tissues is relatively strong. Finerenone does not cross the blood-brain barrier (BBB), and does not reach the central nervous system. The central MR, esp","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uric acid and hypertension: insights from the joint symposium.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-21 DOI: 10.1038/s41440-025-02192-1

Masanari Kuwabara, Shigeru Shibata, Einosuke Mizuta, Atsushi Tanaka, Tatsuya Maruhashi, Ichiro Hisatome, Atsuhiro Ichihara, Takuya Tsuchihashi

引用次数: 0

The voices of elementary school students can change the rate of hypertension control in the community! ~One Healthy Wall Newspaper Moved Us~.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-21 DOI: 10.1038/s41440-025-02190-3

Tetsuro Yoshida

引用次数: 0

Sex differences in the relationship between obesity and hypertension in Japan: a large population-based cross-sectional study.

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-19 DOI: 10.1038/s41440-025-02187-y

Tomomi Nagahata, Nagako Okuda, Kozo Tanno, Yuki Yonekura, Aya Higashiyama, Hirokazu Taniguchi, Koki Kosami, Akira Okayama

We examined the effect of sex on the relationship between obesity and hypertension among Japanese people, who generally have a lower prevalence of obesity than Westerners. We analyzed the results of specific health checkups for Japanese aged 40-74 years (688,306 men and 891,191 women) obtained in 2011. The participants were divided into four age groups (40-49, 50-59, 60-69, and 70-74 years) and five body mass index (BMI) categories (≤ 24.9 [non-overweight/obesity], 25.0-26.9 and 27.0-29.9 [overweight], 30.0-34.9 and ≥ 35.0 kg/m² [obesity]). The odds ratio for hypertension in each BMI category was calculated using normal weight as the reference. The prevalence of hypertension was 26.8%-65.5% for men and 17.6%-53.6% for women in the overweight or obesity categories in the 40-49 age group, and 72.0%-88.7% for men and 70.1%-90.6% for women in the 70-74 age group. In women aged 40-49, the prevalence of hypertension in each BMI category was approximately 10% lower than that in men, but there was almost no difference between men and women in the 70-74 age group. On the other hand, the odds ratio for hypertension was higher in women than in men across all BMI categories and age groups. A stronger relationship between obesity and hypertension was observed in women than in men in all age groups. Japanese women have not been the target of studies for obesity, but more attention should be paid to Japanese women with obesity.

{"title":"Sex differences in the relationship between obesity and hypertension in Japan: a large population-based cross-sectional study.","authors":"Tomomi Nagahata, Nagako Okuda, Kozo Tanno, Yuki Yonekura, Aya Higashiyama, Hirokazu Taniguchi, Koki Kosami, Akira Okayama","doi":"10.1038/s41440-025-02187-y","DOIUrl":"https://doi.org/10.1038/s41440-025-02187-y","url":null,"abstract":"We examined the effect of sex on the relationship between obesity and hypertension among Japanese people, who generally have a lower prevalence of obesity than Westerners. We analyzed the results of specific health checkups for Japanese aged 40-74 years (688,306 men and 891,191 women) obtained in 2011. The participants were divided into four age groups (40-49, 50-59, 60-69, and 70-74 years) and five body mass index (BMI) categories (≤ 24.9 [non-overweight/obesity], 25.0-26.9 and 27.0-29.9 [overweight], 30.0-34.9 and ≥ 35.0 kg/m2 [obesity]). The odds ratio for hypertension in each BMI category was calculated using normal weight as the reference. The prevalence of hypertension was 26.8%-65.5% for men and 17.6%-53.6% for women in the overweight or obesity categories in the 40-49 age group, and 72.0%-88.7% for men and 70.1%-90.6% for women in the 70-74 age group. In women aged 40-49, the prevalence of hypertension in each BMI category was approximately 10% lower than that in men, but there was almost no difference between men and women in the 70-74 age group. On the other hand, the odds ratio for hypertension was higher in women than in men across all BMI categories and age groups. A stronger relationship between obesity and hypertension was observed in women than in men in all age groups. Japanese women have not been the target of studies for obesity, but more attention should be paid to Japanese women with obesity.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on "Association of nighttime very short-term blood pressure variability determined by pulse transit time with adverse prognosis in patients with heart failure".

IF 4.3 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research

Pub Date : 2025-03-18 DOI: 10.1038/s41440-025-02189-w

Fengyu Chen, Chunming Zhang, Kan Kan, CuiCui Wang, Zejun Xue, Jun Zhang

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Hypertension Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀